- CANDID-CNS TM achieves an 83% success rate for predicting small molecule brain penetration and distribution versus a 64% success rate for the industry standard CNS-MPO score - Only ~2% of small ...
This episode of the Pharmaron DMPK Insights Podcast Series sees Scott Summerfield (Senior Director and Head of Pharmaceutical Metabolism at Pharmaron) and Professor Elizabeth de Lange Professor in ...
CANDID-CNS™ is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small molecules compared to 56% by Pfizer’s CNS MPO. CANDID-CNS™ distinguishes CNS penetrant ...
The emergence of human induced pluripotent stem cell (hiPSC) technology has led to the development of several useful 3D in vitro modelling platforms for the study of tauopathy. However, most of these ...
Insilicotrials Technologies SpA has entered into a collaborative partnership with Axoltis Pharma SA in the field of central nervous system (CNS) diseases, with the aim of optimizing the clinical ...
Assessment of electronic health record (EHR) –based machine learning (ML) in predicting risk of brain metastasis among patients with early-stage non–small-cell lung cancer (eNSCLC). This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results